Case report of a neonate with ocular toxoplasmosis due to congenital infection: estimation of the percentage of ocular toxoplasmosis in Greece caused by congenital or acquired infection
Received 20 July 2013
Accepted for publication 2 September 2013
Published 21 November 2013 Volume 2013:7 Pages 2249—2252
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Ioannis Asproudis,1 Ioannis Koumpoulis,1 Chris Kalogeropoulos,1 Georgios Sotiropoulos,1 Margarita Papassava,2 Miltiadis Aspiotis1
1Department of Ophthalmology, Medical School, University of Ioannina, 2Neonatal Intensive Care Unit, University Hospital of Ioannina, Ioannina, Greece
Abstract: We report a case of a newborn male child with congenital toxoplasmosis. During pregnancy seroconversion occurred and positive titers of antitoxoplasmic antibodies (immunoglobulin M and G) were found in the mother, in the third trimester. She received treatment with spiramycin. After birth, the neonate presented with chorioretinitis and intracranial calcifications. The neonate received treatment with pyrimethamine, sulfadiazine, and leucovorin for 1 year. In addition to using a previously described method, we report for the first time in Greece an estimation regarding the percentage of ocular toxoplasmosis caused by congenital or acquired infection. We estimate that ocular toxoplasmosis in Greece is caused in 7% of the cases by congenital infection, and in 93% of the cases by acquired infection.
Keywords: toxoplasmosis, ocular, congenital, acquired, chorioretinitis
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.